Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data

Introduction: In addition to several pharmacodynamics advantages over bosentan, macitentan has once-a-day profile, less liver toxicity and drug interactions, and outcome data showing improved mortality and morbidity in pulmonary arterial hypertension (PAH) patients. We aimed to examine the effect of switching bosentan to macitentan on clinical status of PAH patients. Methods and Results: We conducted a retrospective observational...